SGX:C76.SI 26 August 2025

April 30, 2026, 5:46 PM EDT. Bristol Myers Squibb's stock jumped over 5% after the company reported a 3% rise in first-quarter revenue to $11.5 billion, driven by a 12% sales increase in its growth portfolio. Despite a decline in non-GAAP net income to $3.2 billion, the firm beat Wall Street estimates of $1.42 per share adjusted earnings. The growth portfolio, excluding the cancer drug Opdivo, saw broad sales gains, while the legacy portfolio mostly declined except for blood thinner Eliquis. Management reaffirmed 2026 guidance with revenues projected between $46 billion and $47.5 billion, and adjusted earnings per share forecasted at $6.05 to $6.35. Investors responded positively, underpinning Bristol Myers Squibb's profile as a dynamic name in pharmaceuticals.